Arterial stiffness and functional properties in chronic kidney disease patients on different dialysis modalities: An exploratory study

Nephrology Dialysis Transplantation

Volumn 25, Issue 12, 2010, Pages 4031-4041

  Chung, Ada W Y ^a   Yang, H H Clarice ^a   Kim, Jong Moo ^a   Sigrist, Mhairi K ^b   Brin, Genevieve ^b   Chum, Elliott ^b   Gourlay, William A ^b   Levin, Adeera ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

chronic kidney disease; haemodialysis; oxidative stress; peritoneal dialysis; vasomotor function

Indexed keywords

8 ISOPROSTANE; PHOSPHATE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SUPEROXIDE DISMUTASE; XANTHINE OXIDASE;

ADULT; ARTERIAL STIFFNESS; ARTICLE; BLOOD VESSEL FUNCTION; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; EPIGASTRIC ARTERY; EXPLORATORY RESEARCH; FEMALE; HEMODIALYSIS; HUMAN; HUMAN TISSUE; MALE; OXIDATIVE STRESS; PERITONEAL DIALYSIS; PRIORITY JOURNAL; PULSE WAVE; VASOCONSTRICTION; VASODILATATION;

ADULT; AGED; BLOOD FLOW VELOCITY; CHRONIC DISEASE; ELASTICITY; EPIGASTRIC ARTERIES; FEMALE; HUMANS; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; OXIDATIVE STRESS; PERITONEAL DIALYSIS; RENAL DIALYSIS; VASOCONSTRICTION; VASOMOTOR SYSTEM;

EID: 78649522622     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfq202     Document Type: Article

References (34)

1. Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: effects on the cardiovascular system. Circulation 2007; 116: 85-97
2. Go AS, Chertow GM, Fan D et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305
3. Blacher J, Guerin AP, Pannier B et al. Impact of aortic stiffness on survival in end-stage renal disease. Circulation 1999; 99: 2434-2439
4. Van Guldener C, Janssen MJ, Lambert J et al. Endothelium-dependent vasodilatation is impaired in peritoneal dialysis patients. Nephrol Dial Transplant 1998; 13: 1782-1786
5. Miyazaki H, Matsuoka H, Itabe H et al. Hemodialysis impairs endo-thelial function via oxidative stress: effects of vitamin E-coated dia-lyzer. Circulation 2000; 101: 1002-1006
6. Zoccali C, Mallamaci F, Parlongo S et al. Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation 2002; 105: 1354-1359 (Pubitemid 34260428)
7. Shichiri M, Hirata Y, Ando K et al. Plasma endothelin levels in hypertension and chronic renal failure. Hypertension 1990; 15: 493-496
8. Safar ME, London GM, Plante GE. Arterial stiffness and kidney function. Hypertension 2004; 43: 163-168
9. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 2000; 87: 840-844
10. Himmelfarb J, Stenvinkel P, Ikizler TA et al. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 2002; 62: 1524-1538
11. Faraci FM, Didion SP. Vascular protection: superoxide dismutase isoforms in the vessel wall. Arterioscler Thromb Vasc Biol 2004; 24: 1367-1373
12. Bayés B, Pastor MC, Bonal J et al. Oxidative stress, inflammation and cardiovascular mortality in haemodialysis-role of seniority and intravenous ferrotherapy: analysis at 4 years of follow-up. Nephrol Dial Transplant 2006; 21: 984-990
13. Handelman GJ, Walter MF, Adhikarla R et al. Elevated plasma F2-isoprostanes in patients on long-term hemodialysis. Kidney Int 2001; 59: 1960-1966
14. Lounsbury KM, Hu Q, Ziegelstein RC. Calcium signaling and oxidant stress in the vasculature. Free Radic Biol Med 2000; 28: 1362-1369
15. Chung AW, Yang HH, Sigrist MK et al. Differential microvasculature dysfunction in living kidney donor transplant recipients: nondialyzed versus dialyzed chronic kidney disease patients. J Vasc Res 2010; 47: 128-138
16. Chung AW, Yang HH, Kim JM et al. Upregulation of matrix metallo-proteinase-2 in the arterial vasculature contributes to stiffening and vasomotor dysfunction in patients with chronic kidney disease. Circulation 2009; 120: 792-801
17. Chung AW, Yang HH, Sigrist MK et al. Matrix metalloproteinase-2 and -9 exacerbate arterial stiffening and angiogenesis in diabetes and chronic kidney disease. Cardiovasc Res 2009; 84: 494-504
18. Shoji T, Emoto M, Shinohara K et al. Diabetes mellitus, aortic stiffness, and cardiovascular mortality in end-stage renal disease. J Am Soc Nephrol 2001; 12: 2117-2124
19. Lim PS, Chang YM, Thien LM et al. 8-iso-prostaglandin F2alpha as a useful clinical biomarker of oxidative stress in ESRD patients. Blood Purif 2002; 20: 537-542
20. Amann K, Törnig J, Nichols C et al. Effect of ACE inhibitors, calcium channel blockers and their combination on renal and extrare-nal structures in renal failure. Nephrol Dial Transplant 1995; 10: 33-38
21. Covic A, Goldsmith DJ, Florea L et al. The influence of dialytic modality on arterial stiffness, pulse wave reflections, and vasomotor function. Perit Dial Int 2004; 24: 365-372
22. Blacher J, Demuth K, Guerin AP et al. Influence of biochemical alterations on arterial stiffness in patients with end-stage renal disease. Arterioscler Thromb Vasc Biol 1998; 18: 535-541 (Pubitemid 28177892)
23. Tsai JC, Kuo HT, Chiu YW et al. Correlation of plasma homocyst-eine level with arterial stiffness and pulse pressure in hemodialysis patients. Atherosclerosis 2005; 182: 121-127
24. Adeney KL, Siscovick DS, Ix JH et al. Association of serum phosphate with vascular and valvular calcification in moderate CKD. J Am Soc Nephrol 2009; 20: 381-387
25. Kerr PG, Argiles A, Mion C. Whole blood serotonin levels are markedly elevated in patients on dialytic therapy. Am J Nephrol 1992; 12: 14-18
26. Demuth K, Blacher J, Guerin AP et al. Endothelin and cardiovascular remodelling in end-stage renal disease. Nephrol Dial Transplant 1998; 13: 375-383
27. Chesterton LJ, McIntyre CW. The assessment of baroreflex sensitivity in patients with chronic kidney disease: implications for vaso-motor instability. Curr Opin Nephrol Hypertens 2005; 14: 586-591
28. Lebel M, Grose JH, Kingma I et al. Plasma endothelin levels and blood pressure in hemodialysis and in CAPD patients. Effect of subcutaneous erythropoietin replacement therapy. Clin Exp Hypertens 1994; 16: 565-575
29. Mortier S, De Vriese AS, Van de Voorde J et al. Hemodynamic effects of peritoneal dialysis solutions on the rat peritoneal membrane: role of acidity, buffer choice, glucose concentration, and glucose degradation products. J Am Soc Nephrol 2002; 13: 480-489
30. Morawietz H, Erbs S, Holtz J et al. Endothelial Protection, AT1 blockade and Cholesterol-Dependent Oxidative Stress: the EPAS trial. Circulation 2006; 114: I296-I301
31. Gris JC, Branger B, Vécina F et al. Increased cardiovascular risk factors and features of endothelial activation and dysfunction in dialyzed uremic patients. Kidney Int 1994; 46: 807-813
32. Mittermayer F, Schaller G, Pleiner J et al. Asymmetrical dimethylar-ginine plasma concentrations are related to basal nitric oxide release but not endothelium-dependent vasodilation of resistance arteries in peritoneal dialysis patients. J Am Soc Nephrol 2005; 16: 1832-1838
33. Chen CK, Liaw JM, Juang JG et al. Antioxidant enzymes and trace elements in hemodialyzed patients. Biol Trace Elem Res 1997; 58: 149-157
34. Boaz M, Smetana S, Weinstein T et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet 2000; 356: 1213-1218